Last reviewed · How we verify
ATR-258
At a glance
| Generic name | ATR-258 |
|---|---|
| Also known as | Placebo |
| Sponsor | Atrogi AB |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Biased GRK Signaling Via β2-Adrenergic Receptors in Human Skeletal Muscle (PHASE2)
- The Attractive 2 Trial - Pharmacokinetics of ATR-258 Oral Capsule vs. Oral Solution Formulations in Healthy Volunteers (PHASE1)
- First-in-human Single and Multiple Dose Trial of ATR-258 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ATR-258 CI brief — competitive landscape report
- ATR-258 updates RSS · CI watch RSS
- Atrogi AB portfolio CI